This is a StreetInsider.com Premium Only Page

Fate Therapeutics (FATE) – StreetInsider.com Reports

Apr 18, 2024 04:04 PM Fate Therapeutics (FATE) Files for Up to 3.64M Share Offering by Selling Stockholders

Mar 19, 2024 08:45 AM Fate Therapeutics (FATE) Prices 14.55M Share Offering at $5.50/sh

Feb 28, 2024 07:52 AM Fate Therapeutics (FATE) PT Raised to $7 at Stifel

Feb 27, 2024 09:11 AM Fate Therapeutics (FATE) PT Raised to $7 at Morgan Stanley

Feb 27, 2024 08:17 AM Fate Therapeutics (FATE) PT Lowered to $11 at Canaccord Genuity

Feb 27, 2024 06:39 AM Fate Therapeutics (FATE) PT Raised to $7 at BMO Capital

Feb 27, 2024 05:18 AM Fate Therapeutics (FATE) PT Raised to $7 at Wedbush

Feb 27, 2024 03:13 AM Fate Therapeutics (FATE) PT Raised to $10 at Barclays

Feb 26, 2024 04:08 PM Fate Therapeutics (FATE) Tops Q4 EPS by 7c

Jan 25, 2024 04:29 PM Fate Therapeutics (FATE): Steve Cohen's Point 72 Reports 5% Passive Stake

Nov 20, 2023 06:35 AM Fate Therapeutics (FATE) PT Lowered to $8 at Mizuho Securities

Nov 13, 2023 08:12 AM Fate Therapeutics (FATE) PT Lowered to $3 at Morgan Stanley

Nov 9, 2023 07:59 AM Fate Therapeutics (FATE) PT Lowered to $4.50 at Stifel

Nov 9, 2023 07:10 AM Fate Therapeutics (FATE) PT Lowered to $3 at Wedbush

Nov 9, 2023 06:57 AM Fate Therapeutics (FATE) PT Lowered to $5 at Wells Fargo

Nov 9, 2023 06:48 AM Fate Therapeutics (FATE) PT Raised to $6 at BMO Capital

Nov 8, 2023 04:49 PM Fate Therapeutics (FATE) Files $300M Mixed Shelf

Nov 8, 2023 04:04 PM Fate Therapeutics (FATE) Tops Q3 EPS by 10c

Aug 10, 2023 08:28 AM Fate Therapeutics (FATE) PT Lowered to $5 at Morgan Stanley

Aug 8, 2023 04:17 PM Fate Therapeutics (FATE) Tops Q2 EPS by 5c, misses on revenue

Jun 8, 2023 04:19 PM Fate Therapeutics (FATE) Announces Resignation of Chief Medical Officer

May 4, 2023 08:17 AM Fate Therapeutics (FATE) PT Lowered to $5 at Stifel

May 4, 2023 06:36 AM Fate Therapeutics (FATE) PT Lowered to $5 at Cantor Fitzgerald

May 3, 2023 04:05 PM Fate Therapeutics (FATE) Tops Q1 EPS by 42c

Mar 27, 2023 07:54 AM Wells Fargo Assumes Fate Therapeutics (FATE) at Equal Weight

Mar 1, 2023 02:28 PM Fate Therapeutics (FATE) PT Raised to $10 at Citi

Feb 28, 2023 04:06 PM Fate Therapeutics (FATE) Tops Q4 EPS by 28c

Feb 2, 2023 09:47 AM GT Biopharma (GTBP) Issues Open Letter to Shareholders Detailing Recent Activities

Jan 24, 2023 06:05 AM H.C. Wainwright Downgrades Fate Therapeutics (FATE) to Neutral

Jan 6, 2023 08:28 AM Fate Therapeutics (FATE) collapses 55% after terminating Janssen deal, earns several downgrades

Jan 6, 2023 08:05 AM Cantor Fitzgerald Downgrades Fate Therapeutics (FATE) to Neutral

Jan 6, 2023 07:33 AM Wells Fargo Downgrades Fate Therapeutics (FATE) to Equal Weight

Jan 6, 2023 07:23 AM BofA Securities Downgrades Fate Therapeutics (FATE) to Underperform

Jan 6, 2023 07:08 AM Fate Therapeutics (FATE) PT Lowered to $10 at EF Hutton

Jan 6, 2023 06:59 AM Fate Therapeutics (FATE) PT Lowered to $12 at Mizuho Securities

Jan 6, 2023 06:35 AM Fate Therapeutics (FATE) PT Lowered to $4 at Goldman Sachs

Jan 6, 2023 06:26 AM Wedbush Downgrades Fate Therapeutics (FATE) to Neutral

Jan 6, 2023 06:13 AM Piper Sandler Downgrades Fate Therapeutics (FATE) to Neutral

Jan 6, 2023 06:11 AM Fate Therapeutics (FATE) PT Lowered to $12 at Barclays

Jan 6, 2023 05:36 AM Cowen Downgrades Fate Therapeutics (FATE) to Market Perform

Jan 6, 2023 03:26 AM BMO Capital Downgrades Fate Therapeutics (FATE) to Market Perform

Jan 6, 2023 03:26 AM Truist Securities Downgrades Fate Therapeutics (FATE) to Hold

Jan 6, 2023 03:15 AM Fate Therapeutics (FATE) PT Lowered to $8 at Morgan Stanley

Jan 6, 2023 03:09 AM Fate Therapeutics (FATE) PT Lowered to $5 at Baird

Jan 6, 2023 02:28 AM Stifel Downgrades Fate Therapeutics (FATE ) to Hold

Jan 5, 2023 05:42 PM After-hours movers: CytomX jumps on Moderna deal, WWE gains as McMahon supports possible sale

Jan 5, 2023 05:00 PM Fate Therapeutics (FATE) Announces Termination of Collaboration Agreement with Janssen

Jan 5, 2023 04:58 PM Fate Therapeutics (FATE) Halted, News Pending

Jan 4, 2023 04:05 PM EF Hutton Starts Fate Therapeutics (FATE) at Buy

Jan 3, 2023 06:18 AM Guggenheim Downgrades Fate Therapeutics (FATE) to Neutral